Project Grant R43HL174336
Award Date
9/20/24
Completion Date
8/19/25
Dollars Obligated
$863K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Aquillius Corp (MD8CHERJRF83)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92127, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will evaluate the use of mobile devices to extract vital signs to monitor patients with asthma. The $459,127 award to M5 Enterprise, LLC (doing business as Emedical Sentry) aims to improve the detection and management of asthma attacks through remote patient monitoring. The goal is to enhance telehealth by incorporating video-based vital sign...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $706,806 Project Grant under CFDA 93.837 (Cardiovascular Diseases Research) to Elimu Informatics Inc., a small business software company in California. The grant funds the design, development, and evaluation of TIBSA (Tailored Interoperable Guideline-Based Clinical Decision-Support System for Asthma), a clinical decision support application that incorporates the 2020 NHLBI asthma management guidelines, patient-specific data,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $300,000 to develop a hand-held smart sensor system that can noninvasively detect exhaled volatile organic compound (VOC) biomarkers for predicting pulmonary exacerbations in children with cystic fibrosis. The goal is to leverage machine learning to identify a breath-based biosignature for pulmonary exacerbations, design and test...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,107,276 to Lasarrus Clinic And Research Center Inc. to develop a mobile health system for remote monitoring of patients with Chronic Obstructive Pulmonary Disease (COPD). The project aims to enhance patient adherence to remote monitoring and early symptom recognition, in order to reduce COPD readmissions and healthcare costs. The system utilizes a wearable...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $288,043 to Glycodots LLC to develop a rapid diagnostic test (EPX-RDT) that can detect eosinophil peroxidase (EPX) from nasal swab samples. The goal is to create a non-invasive, point-of-care tool to diagnose and manage asthma by measuring EPX, an important biomarker associated with...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $288,986 to Biotherapeutics, Inc., a biotechnology company in Blacksburg, VA. The grant supports the development of a novel oral immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Determine the safety profile and pharmacokinetics of the new therapeutic in rats, and 2) Characterize the therapeutic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research aims to develop novel physiological markers of high-risk labored breathing to provide advance warning of respiratory failure. The $807,067 award to the Rector & Visitors of the University of Virginia will fund a 5-year study to quantify respiratory kinematics using a new wearable sensor technology called ARK (Analysis of Respiratory Kinematics). The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $347,608 to Biotherapeutics, Inc. to develop a novel, oral, once-daily, immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) determine the translational ability of the therapeutic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $842,408 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Inspire RX LLC, a start-up company based in Ann Arbor, Michigan. The goal of this 18-month project is to refine and further evaluate Inspire RX's "Aerosolve Biohelmet", a personal negative pressure device capable of preventing the spread of aerosolized pathogens while enabling non-invasive oxygen therapies for patients with highly...